The prevalence and treatment patterns of diabetes in the Greek population based on real-world data from the nation-wide prescription database

Liatis, Stavros; Dafoulas, George; Kani, Chara; Politi, Anastasia; Litsa, Panagiota; Sfikakis, Petros P.; Makrilakis, Konstantinos

doi:10.1016/j.diabres.2016.06.018

Cited by 66 publications

(49 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, 67.8% of patients in Southern Italy were treated with metformin in 2012, while 66% of patients were treated with metformin as monotherapy in France in 2013, and 83.6% received metformin in a UK primary care setting in 2013. In a Greek nationwide real‐world data analysis, metformin was the most frequently prescribed medication (77.4%) for T2DM, followed by DPP‐4 inhibitors (44.8%) and sulfonylureas (34.5%), while insulin was used by 19.4% of patients . The national diabetes report of the United States showed that approximately 57% of all patients in 2014 were treated with OADs alone, while approximately 15% of patients were given a combination of insulin and OADs, and insulin monotherapy was established in 14% of patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Regional differences in type 2 diabetes treatment and outcomes in Germany—An analysis of the German DPV and DIVE registries

Hartmann

Bramlage

Lanzinger

et al. 2018

Diabetes Metabolism Res

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…4% of patients 35. The national diabetes report of the United States showed that approximately 57% of all patients in 2014 were treated with OADs alone, while approximately 15% of patients were given a combination of insulin and OADs, and insulin monotherapy was established in 14% of patients.…”

mentioning

confidence: 99%

Regional differences in type 2 diabetes treatment and outcomes in Germany—An analysis of the German DPV and DIVE registries

Hartmann

Bramlage

Lanzinger

et al. 2018

Diabetes Metabolism Res

View full text Add to dashboard Cite

show abstract

“…Mindazonáltal szulfonilureát még minden bizonnyal sokáig fogunk használni, de érdemes az egyes készítmé-nyek eltérő tulajdonságai alapján differenciált szulfonilurea-terápiát folytatni [18]. A metformin előretörése és a szulfonilureák viszonylagos háttérbe szorulása számos országban (Amerikai Egyesült Államok, Egyesült Király-ság, Dánia, Németország, Svédország, Görögország) megfigyelhető volt [19][20][21][22][23][24][25].…”

Section: Táblázatunclassified

A 2-es típusú diabetes antihyperglykaemiás kezelésének alakulása Magyarországon 2001–2014 között – az Országos Egészségbiztosítási Pénztár adatbázis-elemzésének eredményei

et al. 2017

View full text Add to dashboard Cite

A 2-es típusú diabetes mellitus (2TDM) kezelése terén új antidiabetikumok váltak elérhetőkké. A vizsgálat célja az volt, hogy felmérjük a 2TDM gyógyszeres kezelési szokásainak változását 2001-2014 között. A vizsgálatot az Orszá-gos Egészségügyi Pénztár adatbázisának elemzésével végeztük. Az újonnan felismert 2TDM éves előfordulása 75 700 esetről 33 700 esetre csökkent. A 2TDM prevalenciája fokozatosan emelkedett, majd később stagnáló jellegűvé vált (2014-ben 727 000 eset). A szulfonilurea-monoterápia gyakorisága 64%-ról 35%-ra csökkent, a metformin-monoterápia gyakorisága 19%-ról 42%-ra nőtt. Gyógyszeres kezelés szükségessége esetén 2014-ben a metformin volt a leggyakrabban választott első készítmény (66%), ezt követte a szulfonilureák választása (16%). Első alkalommal DPP-4-gátlót 20 362 beteg, GLP-1-mimetikumot pedig 4996 beteg kapott 2014-ben. Öt évvel a szulfonilureakezelés megkezdése után (2010-2014 között) metforminra gyakrabban volt szükség második szerként (39,0%), mint a szulfonilureára öt évvel a metforminkezelés megkezdése után (22,9%). Az antidiabetikumok felírási szokásai az évek során megváltoztak, követve a szakmai irányelvek ajánlásait. Várható, hogy a terápiás szokások a közeljövőben tovább módosulnak. Orv Hetil. 2017; 158(20): 770-778.

show abstract

“…To differentiate type 1 from other types of diabetes, we used case definition criteria based on the review of existing definitions and algorithms [28][29][30][31][32][33][34][35] and available clinical guidelines for type 1 diabetes treatment. None of the existing algorithms were suitable to use in the Irish context for a variety of reasons.…”

Section: Definitionsmentioning

confidence: 99%

“…We also excluded those patients receiving prescriptions for long-acting (basal) insulin only, without any prescription for prandial insulin, as these people are more likely to have type 2 diabetes than type 1 diabetes. 38 39 After initial analysis of different definitions based on the type 1 diabetes specific treatment schemes (online supplementary table 1), algorithms (online supplementary table 2) and comparisons with other existing evidence, [28][29][30][31][32][33][34][35] the following definition was used (see figure 1).…”

Section: Definitionsmentioning

confidence: 99%

Prevalence and incidence of type 1 diabetes in Ireland: a retrospective cross-sectional study using a national pharmacy claims data from 2016

et al. 2020

View full text Add to dashboard Cite

ObjectivesThe aim of this study is to estimate the prevalence and incidence of type 1 diabetes in the Irish population using a national pharmacy claims database in the absence of a national diabetes register.DesignNational, population-based, retrospective, cross-sectional study.SettingCommunity care with data available through the Health Service Executive Pharmacy Claims Reimbursement Scheme from 2011 to 2016.ParticipantsIndividuals with type 1 diabetes were identified by coprescription of insulin and glucometer test strips without any prolonged course (>12 months) of oral hypoglycaemic agents prior to commencing insulin. Those claiming prescriptions for long-acting insulin only, without any prandial insulin, were excluded from the analysis. Incidence was estimated based on the first claim for insulin in 2016, with no insulin use in the preceding 12 months.Main outcome measuresPrevalence of type 1 diabetes in children (<18 years) and adults (≥18 years); incidence of type 1 diabetes in children (≤14 years) and adolescents and adults (>14 years).ResultsThere were 20 081 prevalent cases of type 1 diabetes in 2016. The crude prevalence was 0.42% (95% CI 0.42% to 0.43%). Most prevalent cases (n=17 053, 85%) were in adults with a prevalence of 0.48% (95% CI 0.47% to 0.48%). There were 1527 new cases of type 1 diabetes in 2016, giving an incidence rate of 32 per 100 000 population/year (95% CI 30.5 to 33.7). There was a significant positive linear trend for age, for prevalence (p<0.0001) and incidence (p=0.014). The prevalence and incidence were 1.2-fold and 1.3-fold higher in men than women, respectively. Significant variations in prevalence (p<0.0001) and incidence (p<0.001) between the different geographical regions were observed.ConclusionsThis study provides epidemiological estimates of type 1 diabetes across age groups in Ireland, with the majority of prevalent cases in adults. Establishing a national diabetes register is essential to enable updated epidemiological estimates of diabetes and for planning of services in Ireland.

show abstract

The prevalence and treatment patterns of diabetes in the Greek population based on real-world data from the nation-wide prescription database

Cited by 66 publications

References 24 publications

Regional differences in type 2 diabetes treatment and outcomes in Germany—An analysis of the German DPV and DIVE registries

Regional differences in type 2 diabetes treatment and outcomes in Germany—An analysis of the German DPV and DIVE registries

A 2-es típusú diabetes antihyperglykaemiás kezelésének alakulása Magyarországon 2001–2014 között – az Országos Egészségbiztosítási Pénztár adatbázis-elemzésének eredményei

Prevalence and incidence of type 1 diabetes in Ireland: a retrospective cross-sectional study using a national pharmacy claims data from 2016

Contact Info

Product

Resources

About